DSM to acquire Polymer Technology Group

Amsterdam-based Royal DSM has inked a deal to buy the Polymer Technology Group in Berkeley, CA, making it a world leader in polymers for biomedical research. The financial details were not disclosed, but PTG "expects to exceed USD $40 million in net sales with above-average operating profit margin."

"Through the acquisition of PTG, DSM Biomedical gains a leading global position in the fast-growing biomedical materials market," says Steve Hartig, president of DSM. "Our collective technology in combination with our expanded geographical and customer base will help us to develop a unique portfolio of products for the medical device industry. This will have immediate benefit to PTG's customers."

- check out the press release

Related Article:
Polymers show promise in lab-on-a-chip tech

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.